Industrial Biotechnology Association
Mycogen CEO Jerry Caulder elected chairman of the biotech trade group for 1989-90. He succeeds Schering-Plough Exec VP-Administration Hugh D'Andrade, who will remain on the association's board. Caulder identified some of the key industry issues as health care reimbursement, protection of intellectual property rights, the patent backlog and the release of genetically engineered organisms. Other officers elected to one-year terms are Vice Chairman Stephen Duzan, president, Immunex; Merck Senior VP Charles Leighton, secretary; Calgene CEO Roger Salquist, treasurer; and President Richard Godown. All but Godown also serve as IBA directors.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.